The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2)

ConclusionsDespite being contraindicated in dialysis, eptifibatide was used approximately 3.5 times more frequently than abciximab among dialysis patients undergoing PCI but was associated with similar in‐hospital outcomes.

Source: Journal of Interventional Cardiology - April 1, 2017 Category: Cardiology Authors: Devraj Sukul, Milan Seth, Theodore Schreiber, George Hanzel, Akshay Khandelwal, Louis A. Cannon, Thomas A. Lalonde, Hitinder S. Gurm Tags: ORIGINAL INVESTIGATION Source Type: research